L. Șorodoc *, D. Păduraru **, Luminița Păduraru ***
* Dr. Laurențiu Șorodoc – șef lucrări Clinica de Urgențe Medicale, Spitalul de Urgențe, lași
** Dr. Dumitru Păduraru – șef lucrări Disciplina de Anatomie, U.M.F. lași
*** Dr. Luminița Păduraru – asistent universitar, Clinica de Neonatologie, Spitalul “Cuza Vodă”, Iași
Abstract
Two decades ago, studies of Folkman and colleagues first identified the therapeutic implications of angiogenic growth factors, initially studied in relationship with neoplasm. Investigations and experiments of the last ten years have demonstrated feasibility of using recombinant formulations of such angiogenic growth factors to expedite and/or augment collateral artery development in animal models of myocardial and hindlimb ischemia. This novel strategy for the treatment of vascular insufficiency has been termed “therapeutic angiogenesis”. Experiments in humans, especially for myocardial ischemia are very recent, and the results must pass the exam of time, but the intermediate observations seam to be optimistic, opening a new great option for the therapeutic approach of ischemic heart disease. Certain issues regarding angiogenesis remain unresolved, especially the relative contribution of preexisting, albeit “unused,” collateral vessels versus new vessel formation to newly visible collaterals, which are seen in the setting of tissue ischemia.